Optimizing size and copy number for PEG-fMLF (N-formyl-methionyl-leucyl- phenylalanine) nanocarrier uptake by macrophages

Li Wan, Xiaoping Zhang, Shahriar Pooyan, Matthew S. Palombo, Michael J Leibowitz, Stanley Stein, Patrick J. Sinko

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Curing HIV-1 infection has remained elusive because of low and fluctuating drug levels arising from poor absorption, the development of viral reservoirs and sanctuary sites, toxicity, and patient nonadherence. The present study addresses the issue of insufficient drug exposure in macrophages. Viral reservoir sites such as macrophages are believed to be responsible for the viral rebound effect observed upon the discontinuation of anti-HIV drug therapy. In our proposed model, a drug can be covalently attached to a nanocarrier in order to facilitate the delivery of therapeutic agents to the site(s) of infection. As an initial step, we propose the covalent attachment of several copies of N-forrnyl-Met-Leu-Phe (fMLF), a known chemo-attractant for macrophages. In this article, one or more copies of fMLF were conjugated to multifunctional commercially available or novel, peptide-based PEG nanocarriers in which the structure was varied by appending PEGs with average molecular weights of 5, 20, and 40 kDa. U937 cell-specific binding and cellular uptake were analyzed. The results of uptake studies indicate that (i) uptake is energy dependent and mediated by a fMLF receptor, (ii) appending only 2 copies of the targeting ligand to the multifunctional nanocarrier appears sufficient for binding in vitro, and (iii) of the three configurations studied, the nanocarrier with a molecular weight of about 20 kDa, corresponding to a size of 20-60 nm, demonstrated the highest uptake. The results of the current studies demonstrate the feasibility of targeting macrophages and the suitability of using these synthetically versatile peptide-backbone PEG nanocarriers. The convenience, flexibility and possible limitations of this nanocarrier approach are discussed.

Original languageEnglish (US)
Pages (from-to)28-38
Number of pages11
JournalBioconjugate Chemistry
Volume19
Issue number1
DOIs
StatePublished - Jan 2008
Externally publishedYes

Fingerprint

N-Formylmethionine Leucyl-Phenylalanine
Macrophages
Polyethylene glycols
Peptides
Molecular Weight
Molecular weight
methionyl-leucyl-phenylalanine
Pharmaceutical Preparations
Drug therapy
Anti-HIV Agents
U937 Cells
Feasibility Studies
Patient Compliance
HIV Infections
Toxicity
Curing
HIV-1
Ligands
Drug Therapy
Infection

ASJC Scopus subject areas

  • Chemistry(all)
  • Organic Chemistry
  • Clinical Biochemistry
  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry

Cite this

Optimizing size and copy number for PEG-fMLF (N-formyl-methionyl-leucyl- phenylalanine) nanocarrier uptake by macrophages. / Wan, Li; Zhang, Xiaoping; Pooyan, Shahriar; Palombo, Matthew S.; Leibowitz, Michael J; Stein, Stanley; Sinko, Patrick J.

In: Bioconjugate Chemistry, Vol. 19, No. 1, 01.2008, p. 28-38.

Research output: Contribution to journalArticle

Wan, Li ; Zhang, Xiaoping ; Pooyan, Shahriar ; Palombo, Matthew S. ; Leibowitz, Michael J ; Stein, Stanley ; Sinko, Patrick J. / Optimizing size and copy number for PEG-fMLF (N-formyl-methionyl-leucyl- phenylalanine) nanocarrier uptake by macrophages. In: Bioconjugate Chemistry. 2008 ; Vol. 19, No. 1. pp. 28-38.
@article{67ac0b8a930449e89ffa639cf9f3fee8,
title = "Optimizing size and copy number for PEG-fMLF (N-formyl-methionyl-leucyl- phenylalanine) nanocarrier uptake by macrophages",
abstract = "Curing HIV-1 infection has remained elusive because of low and fluctuating drug levels arising from poor absorption, the development of viral reservoirs and sanctuary sites, toxicity, and patient nonadherence. The present study addresses the issue of insufficient drug exposure in macrophages. Viral reservoir sites such as macrophages are believed to be responsible for the viral rebound effect observed upon the discontinuation of anti-HIV drug therapy. In our proposed model, a drug can be covalently attached to a nanocarrier in order to facilitate the delivery of therapeutic agents to the site(s) of infection. As an initial step, we propose the covalent attachment of several copies of N-forrnyl-Met-Leu-Phe (fMLF), a known chemo-attractant for macrophages. In this article, one or more copies of fMLF were conjugated to multifunctional commercially available or novel, peptide-based PEG nanocarriers in which the structure was varied by appending PEGs with average molecular weights of 5, 20, and 40 kDa. U937 cell-specific binding and cellular uptake were analyzed. The results of uptake studies indicate that (i) uptake is energy dependent and mediated by a fMLF receptor, (ii) appending only 2 copies of the targeting ligand to the multifunctional nanocarrier appears sufficient for binding in vitro, and (iii) of the three configurations studied, the nanocarrier with a molecular weight of about 20 kDa, corresponding to a size of 20-60 nm, demonstrated the highest uptake. The results of the current studies demonstrate the feasibility of targeting macrophages and the suitability of using these synthetically versatile peptide-backbone PEG nanocarriers. The convenience, flexibility and possible limitations of this nanocarrier approach are discussed.",
author = "Li Wan and Xiaoping Zhang and Shahriar Pooyan and Palombo, {Matthew S.} and Leibowitz, {Michael J} and Stanley Stein and Sinko, {Patrick J.}",
year = "2008",
month = "1",
doi = "10.1021/bc070066k",
language = "English (US)",
volume = "19",
pages = "28--38",
journal = "Bioconjugate Chemistry",
issn = "1043-1802",
publisher = "American Chemical Society",
number = "1",

}

TY - JOUR

T1 - Optimizing size and copy number for PEG-fMLF (N-formyl-methionyl-leucyl- phenylalanine) nanocarrier uptake by macrophages

AU - Wan, Li

AU - Zhang, Xiaoping

AU - Pooyan, Shahriar

AU - Palombo, Matthew S.

AU - Leibowitz, Michael J

AU - Stein, Stanley

AU - Sinko, Patrick J.

PY - 2008/1

Y1 - 2008/1

N2 - Curing HIV-1 infection has remained elusive because of low and fluctuating drug levels arising from poor absorption, the development of viral reservoirs and sanctuary sites, toxicity, and patient nonadherence. The present study addresses the issue of insufficient drug exposure in macrophages. Viral reservoir sites such as macrophages are believed to be responsible for the viral rebound effect observed upon the discontinuation of anti-HIV drug therapy. In our proposed model, a drug can be covalently attached to a nanocarrier in order to facilitate the delivery of therapeutic agents to the site(s) of infection. As an initial step, we propose the covalent attachment of several copies of N-forrnyl-Met-Leu-Phe (fMLF), a known chemo-attractant for macrophages. In this article, one or more copies of fMLF were conjugated to multifunctional commercially available or novel, peptide-based PEG nanocarriers in which the structure was varied by appending PEGs with average molecular weights of 5, 20, and 40 kDa. U937 cell-specific binding and cellular uptake were analyzed. The results of uptake studies indicate that (i) uptake is energy dependent and mediated by a fMLF receptor, (ii) appending only 2 copies of the targeting ligand to the multifunctional nanocarrier appears sufficient for binding in vitro, and (iii) of the three configurations studied, the nanocarrier with a molecular weight of about 20 kDa, corresponding to a size of 20-60 nm, demonstrated the highest uptake. The results of the current studies demonstrate the feasibility of targeting macrophages and the suitability of using these synthetically versatile peptide-backbone PEG nanocarriers. The convenience, flexibility and possible limitations of this nanocarrier approach are discussed.

AB - Curing HIV-1 infection has remained elusive because of low and fluctuating drug levels arising from poor absorption, the development of viral reservoirs and sanctuary sites, toxicity, and patient nonadherence. The present study addresses the issue of insufficient drug exposure in macrophages. Viral reservoir sites such as macrophages are believed to be responsible for the viral rebound effect observed upon the discontinuation of anti-HIV drug therapy. In our proposed model, a drug can be covalently attached to a nanocarrier in order to facilitate the delivery of therapeutic agents to the site(s) of infection. As an initial step, we propose the covalent attachment of several copies of N-forrnyl-Met-Leu-Phe (fMLF), a known chemo-attractant for macrophages. In this article, one or more copies of fMLF were conjugated to multifunctional commercially available or novel, peptide-based PEG nanocarriers in which the structure was varied by appending PEGs with average molecular weights of 5, 20, and 40 kDa. U937 cell-specific binding and cellular uptake were analyzed. The results of uptake studies indicate that (i) uptake is energy dependent and mediated by a fMLF receptor, (ii) appending only 2 copies of the targeting ligand to the multifunctional nanocarrier appears sufficient for binding in vitro, and (iii) of the three configurations studied, the nanocarrier with a molecular weight of about 20 kDa, corresponding to a size of 20-60 nm, demonstrated the highest uptake. The results of the current studies demonstrate the feasibility of targeting macrophages and the suitability of using these synthetically versatile peptide-backbone PEG nanocarriers. The convenience, flexibility and possible limitations of this nanocarrier approach are discussed.

UR - http://www.scopus.com/inward/record.url?scp=38949216354&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38949216354&partnerID=8YFLogxK

U2 - 10.1021/bc070066k

DO - 10.1021/bc070066k

M3 - Article

C2 - 18092743

AN - SCOPUS:38949216354

VL - 19

SP - 28

EP - 38

JO - Bioconjugate Chemistry

JF - Bioconjugate Chemistry

SN - 1043-1802

IS - 1

ER -